Literature DB >> 23842115

Defective decatenation checkpoint function is a common feature of melanoma.

Kelly Brooks1, Kee Ming Chia1, Loredana Spoerri1, Pamela Mukhopadhyay1, Matthew Wigan1, Mitchell Stark2, Sandra Pavey1, Brian Gabrielli3.   

Abstract

A hallmark of cancer is genomic instability that is considered to provide the adaptive capacity of cancers to thrive under conditions in which the normal precursors would not survive. Recent genomic analysis has revealed a very high degree of genomic instability in melanomas, although the mechanism by which this instability arises is not known. Here we report that a high proportion (68%) of melanoma cell lines are either partially (40%) or severely (28%) compromised for the G2 phase decatenation checkpoint that normally functions to ensure that the sister chromatids are able to separate correctly during mitosis. The consequence of this loss of checkpoint function is a severely reduced ability to partition the replicated genome in mitosis and thereby increase genomic instability. We also demonstrate that decatenation is dependent on both TopoIIα and β isoforms. The high incidence of decatenation checkpoint defect is likely to be a major contributor to the high level of genomic instability found in melanomas.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23842115     DOI: 10.1038/jid.2013.264

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  33 in total

1.  The G2-phase decatenation checkpoint is defective in Werner syndrome cells.

Authors:  Annapaola Franchitto; Junko Oshima; Pietro Pichierri
Journal:  Cancer Res       Date:  2003-06-15       Impact factor: 12.701

2.  The mitotic spindle checkpoint is a critical determinant for topoisomerase-based chemotherapy.

Authors:  Celia Vogel; Anne Kienitz; Rolf Müller; Holger Bastians
Journal:  J Biol Chem       Date:  2004-12-16       Impact factor: 5.157

3.  Gene expression profiling in melanoma identifies novel downstream effectors of p14ARF.

Authors:  Leisl M Packer; Sandra J Pavey; Glen M Boyle; Mitchell S Stark; Ana L Ayub; Helen Rizos; Nicholas K Hayward
Journal:  Int J Cancer       Date:  2007-08-15       Impact factor: 7.396

Review 4.  Eukaryotic DNA topoisomerase II beta.

Authors:  C A Austin; K L Marsh
Journal:  Bioessays       Date:  1998-03       Impact factor: 4.345

5.  Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.

Authors:  S E Morgan; R S Cadena; S C Raimondi; W T Beck
Journal:  Mol Pharmacol       Date:  2000-02       Impact factor: 4.436

6.  The human decatenation checkpoint.

Authors:  P B Deming; C A Cistulli; H Zhao; P R Graves; H Piwnica-Worms; R S Paules; C S Downes; W K Kaufmann
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

7.  Inhibition of histone deacetylase 3 produces mitotic defects independent of alterations in histone H3 lysine 9 acetylation and methylation.

Authors:  Robyn Warrener; Keeming Chia; William D Warren; Kelly Brooks; Brian Gabrielli
Journal:  Mol Pharmacol       Date:  2010-06-18       Impact factor: 4.436

8.  Topoisomerase IIalpha maintains genomic stability through decatenation G(2) checkpoint signaling.

Authors:  J J Bower; G F Karaca; Y Zhou; D A Simpson; M Cordeiro-Stone; W K Kaufmann
Journal:  Oncogene       Date:  2010-06-21       Impact factor: 9.867

9.  A mouse model for studying the interaction of bisdioxopiperazines with topoisomerase IIalpha in vivo.

Authors:  Morten Grauslund; Annemette Vinding Thougaard; Annette Füchtbauer; Kenneth Francis Hofland; Peter Hansen Hjorth; Peter B Jensen; Maxwell Sehested; Ernst-Martin Füchtbauer; Lars H Jensen
Journal:  Mol Pharmacol       Date:  2007-07-10       Impact factor: 4.436

Review 10.  G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer.

Authors:  N Bucher; C D Britten
Journal:  Br J Cancer       Date:  2008-01-29       Impact factor: 7.640

View more
  12 in total

1.  Mitotic entry upon Topo II catalytic inhibition is controlled by Chk1 and Plk1.

Authors:  Maria Arroyo; Ana Cañuelo; Jesús Calahorra; Florian D Hastert; Antonio Sánchez; Duncan J Clarke; J Alberto Marchal
Journal:  FEBS J       Date:  2020-03-20       Impact factor: 5.542

2.  Dysregulated G2 phase checkpoint recovery pathway reduces DNA repair efficiency and increases chromosomal instability in a wide range of tumours.

Authors:  Madushan Fernando; Pascal H G Duijf; Martina Proctor; Alexander J Stevenson; Anna Ehmann; Shivam Vora; Dubravka Skalamera; Mark Adams; Brian Gabrielli
Journal:  Oncogenesis       Date:  2021-05-15       Impact factor: 7.485

3.  PKCɛ switches Aurora B specificity to exit the abscission checkpoint.

Authors:  Tanya Pike; Nicola Brownlow; Svend Kjaer; Jeremy Carlton; Peter J Parker
Journal:  Nat Commun       Date:  2016-12-22       Impact factor: 14.919

4.  Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells.

Authors:  Jacquelyn J Bower; Leah D Vance; Matthew Psioda; Stephanie L Smith-Roe; Dennis A Simpson; Joseph G Ibrahim; Katherine A Hoadley; Charles M Perou; William K Kaufmann
Journal:  NPJ Breast Cancer       Date:  2017-03-31

Review 5.  Natural Compounds as Anticancer Agents Targeting DNA Topoisomerases.

Authors:  Chetan Kumar Jain; Hemanta Kumar Majumder; Susanta Roychoudhury
Journal:  Curr Genomics       Date:  2017-02       Impact factor: 2.236

Review 6.  Chromosome integrity checkpoints in stem and progenitor cells: transitions upon differentiation, pathogenesis, and aging.

Authors:  Andreas Brown; Hartmut Geiger
Journal:  Cell Mol Life Sci       Date:  2018-07-31       Impact factor: 9.261

7.  Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine.

Authors:  Zay Yar Oo; Martina Proctor; Alexander J Stevenson; Deborah Nazareth; Madushan Fernando; Sheena M Daignault; Catherine Lanagan; Sebastian Walpole; Vanessa Bonazzi; Dubravka Škalamera; Cameron Snell; Nikolas K Haass; Jill E Larsen; Brian Gabrielli
Journal:  Mol Oncol       Date:  2019-06-14       Impact factor: 6.603

8.  MCPH1 Lack of Function Enhances Mitotic Cell Sensitivity Caused by Catalytic Inhibitors of Topo II.

Authors:  María Arroyo; Antonio Sánchez; Ana Cañuelo; Rosalía F Heredia-Molina; Eduardo Martínez-Molina; Duncan J Clarke; Juan Alberto Marchal
Journal:  Genes (Basel)       Date:  2020-04-08       Impact factor: 4.096

9.  A genome-wide RNAi screen identifies the SMC5/6 complex as a non-redundant regulator of a Topo2a-dependent G2 arrest.

Authors:  Katharina Deiss; Nicola Lockwood; Michael Howell; Hendrika Alida Segeren; Rebecca E Saunders; Probir Chakravarty; Tanya N Soliman; Silvia Martini; Nuno Rocha; Robert Semple; Lykourgos-Panagiotis Zalmas; Peter J Parker
Journal:  Nucleic Acids Res       Date:  2019-04-08       Impact factor: 16.971

Review 10.  Cell Cycle-Dependent Control and Roles of DNA Topoisomerase II.

Authors:  Joyce H Lee; James M Berger
Journal:  Genes (Basel)       Date:  2019-10-30       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.